Table 1
Demographic and Clinical Characteristics of the Studied Population
| Primary Blepharospasm (n = 41) | Secondary Blepharospasm (n = 23) | p | |
|---|---|---|---|
| Female, no. (%) | 28 (68.3) | 6 (26.1) | 0.001 |
| Age, mean (SD), years | 69.1 (9.2) | 65.9 (10.2) | 0.22 |
| Caucasian, no. (%) | 36 (87.8) | 21 (91.3) | 0.32 |
| Smoker, no. (%) | 12 (29.3) | 10 (43.5) | 0.33 |
| BMI, mean (SD) | 26.5 (5.5) | 29.3 (7) | 0.13 |
| Years since first symptom, mean (SD) | 14.2 (12.1) | 6.2 (4.7) | <0.001 |
| Years since diagnosis, mean (SD) | 11 (8.8) | 5.7 (4) | 0.002 |
| Duration of follow-up at UF, months (SD) | 42.8 (39.3) | 28.6 (29.5) | 0.17 |
Table 2
Comparison of BoNT Injections between First and Last Sessions at the University of Florida
| Primary (n = 41) | Secondary (n = 23) | p | |
|---|---|---|---|
| First injection | |||
| Dosage in units, mean (SD) | 45.5 (28.4) | 39.3 (24.6) | 0.38 |
| Shots given, mean (SD) | 9.3 (2.7) | 8.8 (1.8) | 0.39 |
| Side effects, no. (%) | 10 (25) | 1 (5) | 0.02 |
| Lateral oculi, no. (%) | 41 (100) | 23 (100) | 1 |
| Pretarsal, no. (%) | 30 (73.2) | 18 (78.3) | 0.65 |
| Corrugator, no. (%) | 12 (29.3) | 8 (34.8) | 0.65 |
| Procerus, no. (%) | 14 (34.1) | 4 (17.4) | 0.15 |
| Frontalis, no. (%) | 8 (19.5) | 1 (4.3) | 0.14 |
| Last injection | |||
| Dosage, mean (SD) | 57.2 (21.4) | 53.5 (21.1) | 0.54 |
| Shots given, mean (SD) | 9.9 (2.3) | 9.9 (1.9) | 0.99 |
| Side effects, no. (%) | 6 (16.2) | 3 (17.6) | 0.89 |
| Lateral oculi, no. (%) | 37 (100) | 19 (100) | 1 |
| Pretarsal, no. (%) | 28 (75.7) | 18 (94.7) | 0.14 |
| Corrugator, no. (%) | 18 (48.6) | 10 (52.6) | 0.78 |
| Procerus, no. (%) | 22 (59.5) | 6 (31.6) | 0.05 |
| Frontalis, no. (%) | 9 (22) | 2 (10.5) | 0.29 |
Figure 1
Chart Demonstrating the Clinical Global Impression Scale between Populations at two time points.
1) First session primary blepharospasm; 2) last session primary blepharospasm; 3) first session secondary blepharospasm; 4) last session secondary blepharospasm.